User:SaraKathryn Kalkhoff/Sandbox 1
From Proteopedia
(Difference between revisions)
Line 3: | Line 3: | ||
== Introduction == | == Introduction == | ||
- | [https://www.sciencedirect.com/topics/medicine-and-dentistry/gastric-inhibitory-polypeptide The Gastric Inhibitory Polypeptide is a ligand that can be bound to its receptor (GIP-R) to help facilitate the breakdown of glucose.] This is the basis of what makes up one of the key ways that glucose is bound and broken down into different parts, including insulin, to be able to maintain blood glucose levels within the body. | + | [https://www.sciencedirect.com/topics/medicine-and-dentistry/gastric-inhibitory-polypeptide The Gastric Inhibitory Polypeptide is a ligand that can be bound to its receptor (GIP-R) to help facilitate the breakdown of glucose.] This is the basis of what makes up one of the key ways that glucose is bound and broken down into different parts, including insulin, to be able to maintain blood glucose levels within the body. With this structure, it is also to work with the GLP-1 receptors found within cells to help break down glucose |
[[Image:Gip.png|300px|right|thumb|Figure 1: Main Structure of the Gastric Inhibitory Polypeptide Receptor (GIP-R).]] | [[Image:Gip.png|300px|right|thumb|Figure 1: Main Structure of the Gastric Inhibitory Polypeptide Receptor (GIP-R).]] | ||
== Function == | == Function == | ||
- | The GIP receptor helps facilitate movement of glucose within a cell. <ref name='Sun'>PMID:35333651</ref>. | + | The GIP receptor helps facilitate movement of glucose within a cell. <ref name='Sun'>PMID:35333651</ref>. It has a natural ligand that is 42 residues and helps kickstart the GIP-R into firing, as a transporter for glucose in and out of the cell. Once the levels become too high, the ligand |
===Tirzepatide=== | ===Tirzepatide=== | ||
- | Tirzepatide has been used as a treatment for Type 2 diabetes. <scene name='10/1037492/Just_tirz/1'>Tirzepatide has a total of 39 residues present in its structure.</scene> It is used to help treat Type 2 Diabetes, as an agonist to allow insulin to be broken down. | + | Tirzepatide has been used as a treatment for Type 2 diabetes. <scene name='10/1037492/Just_tirz/1'>Tirzepatide has a total of 39 residues present in its structure.</scene> It is used to help treat Type 2 Diabetes, as an agonist to allow insulin to be broken down. This medication is the result of |
== Disease == | == Disease == | ||
- | Diabetes is | + | Diabetes is a disease that causes |
- | + | ||
== Structural highlights == | == Structural highlights == | ||
<scene name='10/1037492/Gip_tirz/7'>Main scene of Tirzepatide bound to the GIP receptor. </scene> | <scene name='10/1037492/Gip_tirz/7'>Main scene of Tirzepatide bound to the GIP receptor. </scene> | ||
=== Active Site === | === Active Site === | ||
- | Main binding domains between tirzepatide and the GIP receptor would contain an arginine 190 and glutamine 220 residues to facilitate binding of the ligand. One key difference found was a point mutation at position 7 between an Isoleucine and Threonine <ref name='Sun'>PMID:35333651</ref>, which would result in a higher affinity for the tirzepatide molecule binding onto the receptor than the ligand. | + | Main binding domains between tirzepatide and the GIP receptor would contain an arginine 190 and glutamine 220 residues to facilitate binding of the ligand. One key difference found was a point mutation at position 7 between an Isoleucine and Threonine <ref name='Sun'>PMID:35333651</ref>, which would result in a higher affinity for the tirzepatide molecule binding onto the receptor than the ligand. |
[[Image:i7_vs_t7.png|300px|left|thumb|Figure 2: Key difference between GIP ligand and Tirzepatide at position 7. Ile7 is in pink (ligand), and Thr7 is in green (tirzepatide).]] | [[Image:i7_vs_t7.png|300px|left|thumb|Figure 2: Key difference between GIP ligand and Tirzepatide at position 7. Ile7 is in pink (ligand), and Thr7 is in green (tirzepatide).]] | ||
== References == | == References == |
Revision as of 12:55, 9 April 2024
|